Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q2 FY26
Investor Presentation
Q4 FY25
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY23
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
5
Neutral
5
Bullish
4
Bearish
8
Neutral
5
Bullish
33
Bearish
3
Neutral
0
Bullish
29
Discovery themes featuring this stockDiscovery themes featuring this stock| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
248.25 | 268 Cr | 32.62 | 4.28 | 0.00 | 13.28 | 18.53 | 9.99 | ||
67.05 | 194 Cr | 46.30 | 3.76 | 0.00 | 11.99 | 14.14 | 7.06 | ||
58.25 | 143 Cr | 42.14 | 2.67 | 0.00 | 6.13 | 8.59 | 5.07 | ||
72.94 | 136 Cr | 6.88 | 1.32 | 0.00 | 18.49 | 23.03 | 13.19 | ||
87.40 | 122 Cr | 15.69 | 2.40 | 0.00 | 35.97 | 39.64 | 0.00 | ||
76.00 | 116 Cr | 12.96 | 2.02 | 0.00 | 43.27 | 33.60 | 13.89 | ||
99.85 | 70 Cr | 37.69 | 2.86 | 0.00 | 6.75 | 9.64 | 2.85 | ||
| Median: 7 Co. | — | 76.00 | 136 Cr | 32.62 | 2.67 | 0.00 | 13.28 | 18.53 | 7.06 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Vaidya Sane Ayurved Laboratories Limited (Madhavbaug) specializes in integrative Ayurvedic healthcare, focusing on disease reversal for cardiac issues, diabetes, hypertension, and obesity through its extensive clinic network and hospitals.
Recent half-year financials reflected robust growth, with a 19.48% increase in revenue compared to the prior year, driven by enhanced patient engagement and a strategic shift towards disease reversal programs.
Madhavbaug is committed to scaling its operations with substantial plans for hospital capacity expansion and infrastructure augmentation, ensuring wider accessibility to its unique treatment methodologies across India.
The international collaboration with Maxura Healthcare in Malaysia positions Madhavbaug to explore global markets, enhancing its brand reach and integrating Ayurvedic therapies into a broader international healthcare paradigm.
Healthcare Services
Healthcare Service Provider
268 Cr
Low Risk
32.6
56.7
2.7
4.3
335.00
125.00
Sales CAGR
Profit CAGR
ROE
ROCE
Vaidya Sane Ayurved Laboratories Ltd (MADHAVBAUG) is currently trading at 241.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Vaidya Sane Ayurved Laboratories Limited (Madhavbaug) specializes in integrative Ayurvedic healthcare, focusing on disease reversal for cardiac issues, diabetes, hypertension, and obesity through its extensive clinic network and hospitals. Recent half-year financials reflected robust growth, with a 19.48% increase in revenue compared to the prior year, driven by enhanced patient engagement and a strategic shift towards disease reversal programs. Madhavbaug is committed to scaling its operations with substantial plans for hospital capacity expansion and infrastructure augmentation, ensuring wider accessibility to its unique treatment methodologies across India. The international collaboration with Maxura Healthcare in Malaysia positions Madhavbaug to explore global markets, enhancing its brand reach and integrating Ayurvedic therapies into a broader international healthcare paradigm.
Over the past 52 weeks, Vaidya Sane Ayurved Laboratories Ltd has traded between a low of ₹125.00 and a high of ₹335.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Vaidya Sane Ayurved Laboratories Ltd has a market capitalization of approximately 267.78. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Vaidya Sane Ayurved Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 32.62 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 267.78 Cr, Vaidya Sane Ayurved Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Vaidya Sane Ayurved Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Vaidya Sane Ayurved Laboratories Ltd is 32.62. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
